Table 1.
Characteristics of recipients of autologous, HLA-identical sibling or unrelated/mismatched related donor HCT for BL
| Autologous N (%) |
HLA-identical sibling N (%) |
Unrelated/ mismatched related N (%) |
P-value | |
|---|---|---|---|---|
| Number of patients | 113 | 80 | 48 | |
| Age, median (range), years | 31 (5–76) | 24 (3–55) | 22 (2–54) | <0.001 |
| Age at transplant | 0.005 | |||
| <10 yrs | 6 (5) | 10 (13) | 10 (21) | |
| 10–19 yrs | 26 (23) | 22 (28) | 12 (25) | |
| 20–29 yrs | 21 (19) | 21 (26) | 10 (21) | |
| 30–39 yrs | 20 (18) | 15 (19) | 8 (17) | |
| 40–49 yrs | 14 (12) | 7 (9) | 6 (13) | |
| 50–59 yrs | 12 (11) | 5 (6) | 2 (4) | |
| ≥60 yrs | 14 (12) | 0 | 0 | |
| Male Sex | 79 (70) | 53 (66) | 39 (81) | 0.183 |
| Karnofsky score at HCT <90% | 32 (28) | 29 (36) | 23 (48) | 0.184 |
| Interval from diagnosis to transplant, median (range), months | 7 (2–74) | 6 (1–29) | 9 (1–113) | 0.002 |
| Disease stage at diagnosis | 0.076 | |||
| I–II | 34 (30) | 14 (18) | 19 (40) | |
| III–IV | 76 (67) | 50 (63) | 26 (54) | |
| Unknown | 3 (3) | 16 (20) | 3 (6) | |
| Number of prior chemotherapy lines | 0.032 | |||
| 1 | 26 (23) | 9 (11) | 4 (8) | |
| 2 | 42 (37) | 23 (29) | 17 (35) | |
| 3 or more | 25 (22) | 18 (23) | 22 (46) | |
| Missing | 20 (18) | 30 (38) | 5 (10) | |
| Rituxan prior to Tx | 6 (5) | 11 (14) | 12 (25) | 0.002 |
| Methotrexate or Cytarabine prior to HCT | 46(32) | 28(35) | 33(69) | <0.001 |
| Reduced Intensity Conditioning | NA | 10 (13) | 4 (8) | 0.556 |
| Conditioning regimen details-allogeneic group | NA | 0.609 | ||
| Cy+TBI | 52 (65) | 32 (67) | ||
| Bu+Cy | 12 (15) | 5 (10) | ||
| CY + Etoposide based | 6 (8) | 1 (2) | ||
| Others (Low dose TBI, BU, MEL) | 10(12) | 10(20) | ||
| Conditioning regimen-autologous group | NA | NA | NA | |
| TBI-based | 30 (27) | |||
| BEAM and similar | 62 (55) | |||
| CBV or similar | 12 (11) | |||
| BuMEL/BuCy | 6 (5) | |||
| Others | 3 (3) | |||
| Extranodal involvement at diagnosis | 80 (71) | 40 (50) | 35 (73) | <0.001 |
| Marrow involvement at diagnosis | 25 (22) | 17 (21) | 13 (27) | 0.011 |
| CNS involvement at diagnosis | 13 (12) | 10 (13) | 5 (10) | 0.398 |
| Disease status prior to transplant | 0.001 | |||
| PIF sensitive | 13 (12) | 8 (9) | 8 (17) | |
| PIF resistant | 5 (4) | 3 (4) | 4 (8) | |
| CR1 | 48 (42) | 27 (34) | 3 (6) | |
| REL sensitive | 17 (15) | 3 (4) | 6 (13) | |
| REL resistant | 3 (3) | 4 (5) | 6 (13) | |
| CR2 or beyond | 19 (17) | 23 (29) | 16 (33) | |
| Unknown | 8 (7) | 12 (15) | 5 (10) | |
| Chemotherapy sensitivity at transplant | 0.011 | |||
| Sensitive | 97 (86) | 62 (78) | 34 (71) | |
| Graft type | <0.001 | |||
| Bone marrow | 31 (27) | 55 (69) | 32 (67) | |
| Peripheral blood | 82 (73) | 25 (31) | 8 (17) | |
| Cord blood | 0 | 0 | 8 (17) | |
| Year of HCT | <0.001 | |||
| 1985–1988 | 1 (1) | 17 (21) | 0 | |
| 1989–1992 | 21 (19) | 10 (13) | 2 (4) | |
| 1993–1996 | 31 (27) | 16 (20) | 7 (15) | |
| 1997–2000 | 38 (34) | 16 (20) | 9 (19) | |
| 2001–2004 | 16 (14) | 15 (19) | 19 (40) | |
| 2005–2007 | 6 (5) | 6 (8) | 11 (23) | |
| GVHD prophylaxis | NA | <0.001 | ||
| T-cell depletion | 13 (16) | 5 (10) | ||
| FK506+MTX+-other | 4 (5) | 16 (33) | ||
| CsA+MTX+-other | 41 (51) | 27 (56) | ||
| Median follow-up of survivors, months | 79 (9–222) | 56 (4–233) | 50 (26–160) |
Abbreviations NA = not applicable; CR = complete remission; PIF = primary induction failure; REL = relapse; CY = cyclophosphamide, GVHD = graft versus host disease; MTX = methotrexate; CsA = cyclosporine; FK506 = tacrolimus.